Marc Lippman

Marc Lippman has made foundational contributions to understanding breast cancer biology and the role of residual disease in treatment failure, with decades of research elucidating hormone receptor signaling and endocrine resistance mechanisms. His work on tumor dormancy has provided critical insights into why minimal residual disease can persist for years before clinical relapse in breast cancer patients. He has been instrumental in integrating molecular biomarkers into adjuvant therapy decision-making frameworks.